Madrigal Pharmaceuticals Correlations

MDGL Stock  USD 334.13  14.60  4.19%   
The current 90-days correlation between Madrigal Pharmaceuticals and Akero Therapeutics is 0.31 (i.e., Weak diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Madrigal Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Madrigal Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction.

Madrigal Pharmaceuticals Correlation With Market

Very weak diversification

The correlation between Madrigal Pharmaceuticals and DJI is 0.48 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Madrigal Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.

Moving together with Madrigal Stock

  0.61MRK Merck CompanyPairCorr

Moving against Madrigal Stock

  0.5BCH Banco De ChilePairCorr
  0.58TRV The Travelers CompaniesPairCorr
  0.42PG Procter GamblePairCorr
  0.38WMT Walmart Sell-off TrendPairCorr
  0.33DIS Walt DisneyPairCorr

Related Correlations Analysis

Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Risk-Adjusted Indicators

There is a big difference between Madrigal Stock performing well and Madrigal Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Madrigal Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Madrigal Pharmaceuticals Corporate Management

Justin DrinkwineSenior VPProfile
Thomas HareSenior ManagementProfile
Remy SukhijaVP OfficerProfile
PharmD MBASenior AffairsProfile
Mark UnderwoodExecutive OperationsProfile